Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is well-positioned to see significant revenue growth in the coming years, driven by multiple catalysts such as the potential approval of Afrezza for pediatric use, the approval of the FUROSCIX ReadyFlow autoinjector, and positive results from the MNKD-201 Phase 1b study in IPF patients. The company also has a strong balance sheet and is undervalued compared to its potential revenue and earnings growth potential in the future. These factors make MannKind a promising investment opportunity with a favorable risk-reward scenario.

Bears say

MannKind is currently overvalued with a price target of $10 and has a high risk profile due to its dependence on commercial execution, clinical trials, and regulatory approvals. Despite potential positive developments with their Tyvaso DPI and Ralinepag DPI products, uncertainty surrounding partnership agreements and future sales projections create further risk for investors to consider. With a decline in projected royalty revenue from 2027 onwards and a high amount of risk, it may be best to avoid investing in this stock.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.